Thursday, April 14, 2016

BRIEF-Oncolytics Biotech reports updated data from Phase 2 study of REOLYSIN

* Analysis showed a statistically significantly higher

percentage of patients surviving two years in test arm versus

control arm

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)